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Abstract 
Dravet syndrome is an intractable epileptic syndrome beginning in the first year of life. 
De novo mutations of SCN1A, which encode the Nav1.1 neuronal voltage-gated sodium 
channel, are considered a major cause of Dravet syndrome. We investigated genetic 
modifiers of this syndrome.  
We performed a mutational analysis of all coding exons of CACNA1A in 48 patients 
with Dravet syndrome. To assess the effects of CACNA1A variants on SCN1A 
mutations, we compared clinical features in two genotype groups; patients harboring 
SCN1A mutations but no CACNA1A variants (n = 20), and patients with SCN1A 
mutations plus CACNA1A variants (n = 20). CACNA1A variants which were detected in 
the patients were studied using heterologous expression of recombinant human Cav2.1 
in HEK 293 cells and whole-cell patch-clamp recording. 
Nine variants including six novel variants were detected in 21 (43.8%) of 48 patients. 
One double heterozygous variant, R1126H + R2201Q, was significantly more frequent 
in patients with Dravet syndrome than healthy individuals. The patients harboring 
SCN1A mutations and CACNA1A variants had an earlier onset of seizures and more 
frequent prolonged-seizures before 1-year-of-age than the patients with only SCN1A 
mutations. The electrophysiological properties of four of the five novel Cav2.1 channel 
CACNA1A variants in Dravet syndrome 
 
4 
 
variants exhibited biophysical changes consistent with gain-of-function. We conclude 
that Cav2.1 channel variants occur in some Dravet syndrome patients and could be 
potential genetic modifiers.
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Introduction 
Dravet syndrome (or severe myoclonic epilepsy in infancy, SMEI, MIM# 607208) is 
an intractable epileptic syndrome characterized by various types of seizures beginning 
in the first year of life with prolonged seizures which are often provoked by fever 
(Dravet et al., 2005). De novo mutations of SCN1A, which encodes the Nav1.1 neuronal 
voltage-gated sodium channel are detected in approximately 70-80% of the patients 
with Dravet syndrome, therefore, SCN1A mutations have been considered to be a major 
cause of this syndrome (Claes et al., 2001; Ohmori et al., 2002; Depienne et al., 2009). 
However, several studies have suggested that environmental factors and genetic 
modifiers could influence the clinical phenotype of Dravet syndrome. The patients with 
the same mutation of SCN1A often show different severities of epilepsy (Depienne et al., 
2010; Suls et al., 2010; Guerrini et al., 2010), and approximately 50% of the patients 
with Dravet syndrome have a family history of convulsive disorders including febrile 
seizures and benign epilepsy (Dravet et al., 2005; Hattori et al., 2008). Moreover, the 
severity of epilepsy in a SMEI mouse model harboring a truncated SCN1A mutation is 
influenced by its genetic background (Yu et al., 2006). The 129/SvJ mouse strain 
exhibited a decreased incidence of spontaneous seizures and a longer survival in 
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comparison to the C57BL/6J mice. Therefore, genetic background affects the Scn1a KO 
mouse phenotype. 
 Supporting evidence for a multifactorial etiology of Dravet syndrome has been 
reported (Singh et al., 2009). Singh et al. demonstrated that the patients with SCN9A 
variants develop febrile seizures, and 6 of 109 patients with Dravet syndrome had 
missense variants of the SCN9A, in addition to de novo SCN1A mutations. These 
SCN9A missense variants possibly contribute to Dravet syndrome in a multifactorial 
fashion. 
A missense mutation of the CACNB4, which encodes the 4 subunit of the 
voltage-dependent calcium channel, has been detected in a patient with Dravet 
syndrome (Ohmori et al., 2008). This patient had a de novo SCN1A nonsense mutation 
and a CACNB4 missense mutation (R468Q), which was inherited from his father with a 
history of a single febrile seizure. A CACNB4-R468Q electrophysiological study using 
a heterologous expression system revealed increased Cav2.1 (P/Q type) voltage-gated 
calcium channel -current density. A CACNA1A mutational analysis was conducted to 
further assess the role of Cav 2.1 in the patients with Dravet syndrome, because Cav 4 
is the predominant subunit associated with Cav 2.1 (Dolphin, 2003).  
In the present study, we detected nine variants including six novel variants of 
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CACNA1A in the 48 patients. This is the first report of an association between 
CACNA1A variants and Dravet syndrome. 
 
Materials and Methods 
Clinical samples 
A total of 48 patients with Dravet syndrome including typical and borderline cases were 
analyzed for this study. 46 of which had been recruited for our previous studies (Ohmori 
et al., 2002; Hattori et al., 2008). All patients were screened for SCN1A mutations by 
direct sequencing of all coding exons and a multiplex ligation dependent probe 
amplification (MLPA) using SALSA MPLA P137 SCN1A reagent (MRC-Holland, 
Amsterdam, The Netherlands). Forty of the 48 patients (83.3%) had various types of 
mutations (Supplementary Table 1). A hundred and ninety control subjects were 
randomly selected from healthy Japanese volunteers. 
 
Mutational analysis of CACNA1A  
Genomic DNA was extracted from peripheral blood by SDS/proteinase K treatment. All 
coding exons of CACNA1A were analyzed by direct sequencing with primers designed 
outside the exons. The sequences of each sample were compared with the GenBank data 
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base (accession number: NM_023035). A statistical analysis was performed using either 
the Chi-square test or Fisher’s exact two-tailed test.  
The study was approved by the Ethics Committee of Okayama University Graduate 
School of Medicine, Dentistry, and Pharmaceutical Sciences. Written informed consent 
was obtained from the patients’ parents and all healthy participants. 
 
Genotype and phenotype correlation 
The patients were divided into four genotypic groups; a SCN1A mutation plus a 
CACNA1A variant (n = 20), SCN1A mutation but no CACNA1A variant (n = 20), a 
CACNA1A variant but no SCN1A mutation (n = 2), and no SCN1A mutation and no 
CACNA1A variant (n = 6). The first group included a previously reported patient who 
had SCN1A-R568X and CACNB4-R468Q, which led to increased Cav2.1 current 
density (Ohmori et al., 2008). To assess the effects of the variant Cav2.1channels on 
mutant Nav1.1 channels, we compared clinical features between the two genotype 
groups, namely between the patients harboring SCN1A mutations but no CACNA1A 
variants (n = 20), and the patients with SCN1A mutations and CACNA1A variants (n = 
20). The clinical features of the Dravet syndrome change with an increase in age, 
therefore, the genotype-phenotype correlation should be evaluated at the same age in all 
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subjects. The patients’ age ranged from 4 to 43 years. Symptoms before 1 year of age, 
including seizure onset, total number of seizures, total number of prolonged seizures 
lasting for more than 10 min, and type of seizures were assessed. Clinical data were 
collected based on an exhaustive review of the medical records of a previous study 
(Hattori et al., 2008). 
 
Mutagenesis and heterologous expression of human CACNA1A 
Full-length human CACNA1A (Cav2.1) cDNA in pcDNA1.1 and rabbit 2 subunit 
cDNA expression vector, pKCR2, were kindly provided by Prof. T. Tanabe (Tokyo 
Medical and Dental University, Tokyo, Japan). G266S, R1126H, R2201Q, DQER 
2202-2205 deletion, and double variant R1126H + R2201Q were introduced into 
CACNA1A cDNA in pM014X by PCR-based mutagenesis. The entire open reading 
frame of all cDNAs was confirmed by sequencing before use in the experiments. The 
CACNA1A cDNA contained 5’ and 3’ untranslated regions, thus the coding region from 
the first methionine to the stop codon was amplified by PCR and cloned into pMO14X 
mammalian expression vector. A minor-type variant of one single nucleotide 
polymorphism (SNP), serine (agc) at 1108 codon (rs16027), was found for sequence 
confirmation. Therefore, 2.75kb of EcoRI-EcoRI fragment on the cDNA vector was 
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substituted with same sized-DNA fragment containing the major-type glycine (ggc) at 
1108 codon to produce normal CACNA1A cDNA vector. 
Human CACNB4 cDNA was amplified by PCR with a human brain cDNA library. 
The cDNA was confirmed by DNA sequencing, and subcloned into pIRES2-EGFP. 
CACNA1A was coexpressed heterologously with accessory 4 and 2 subunits in 
HEK293 cells by transient plasmid transfection using Qiagen Superfect transfection 
reagent (Qiagen). Approximately 3.8 g of total DNA was transfected (plasmid mass 
ratio was 1: 2: 4= 2:1:0.8). The cells were used for the electrophysiological 
analysis 72 hours after transfection. 
 
Electrophysiological study of CACNA1A 
The currents from HEK293 cells were recorded with the whole-cell patch-clamp 
technique by using the Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA, 
USA). Patch pipettes were fabricated from borosilicate glass (Warner Instrument Co., 
Hamden, CT, USA). Pipette resistance ranged from 2 to 3 MΩ. As a reference electrode, 
a 2% agar bridge with a composition similar to the bath solution was used. The series 
resistance was electronically compensated to >50%. All illustrated and analyzed 
currents were corrected for remaining capacitance and leakage currents using a –P/4 
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procedure. The pipette solution for recordings of the whole-cell currents contained 110 
mM CsOH, 20 mM CsCl, 5 mM MgCl2, 10 mM EGTA, 5 mM MgATP, 5 mM 
creatine-phosphate and 10 mM HEPES; adjusted to pH 7.35 with aspartic acid and an 
osmolarity of 310 mOsmol/kg. The bath solution contained 5 mM BaCl2, 150 mM 
TEA-Cl, 10 mM glucose, and 10 mM HEPES; adjusted to pH 7.4 with TEA-OH and 
osmolarity of 310 mOsmol/kg. Data were sampled at 20 kHz and filtered at 5 kHz. 
Voltage-dependence of activation and inactivation curves were fitted with 
Boltzmann functions to determine the voltages for half-maximal activation and 
inactivation (V1/2) and slope factor (k). Time constants for activation were obtained 
from monoexponential fits to the raw current data. Channel inactivation was evaluated 
by fitting the decay phase of the whole-cell current with the two-exponential function, 
I/Imax = Af × exp(−t/τf) + As × exp(−t/τs) + C, where τf and τs denote time constants 
(fast and slow components, respectively), A represents a fractional amplitude, and C is 
the level of noninactivating current. 
 
Statistical Analysis for electrophysiological study 
   All electrophysiological data are presented as the mean ± SEM, and statistical 
comparisons were made in reference to the wild type by using unpaired Student’s t-test. 
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The threshold p value for statistical significance was 0.05. Data analysis was performed 
by using the Clampfit 8.2 (Axon Instruments, Union City, CA, USA) and OriginPro 7.0 
(OriginLab, Northampton, MA, USA) software packages. 
 
 
Results 
CACNA1A mutational analysis 
Results of the CACNA1A genetic analysis in 48 patients with Dravet syndrome and the 
frequency of the variants in 190 healthy participants are summarized in Table 1. Nine 
variants were detected in 21 patients (43.8%). Three (p.E921D, p.E996V, and 
p.G1108S) of the 9 variants were previously reported (dbSNP: rsl6022, rsl6023, and 
rsl6017, respectively), whereas the remaining 6 (p.G266S, p.K472R, p.A924G, 
p.R1126H, p.R2201Q and p.DQER2202-2205 deletion) were novel. Electropherograms 
of the CACNA1A DNA sequence for the nine variants are shown in Fig. 1A. 
Variant p.G266S was not identified in any of the 188 healthy participants (376 
chromosomes). A combination of p.R1126H and p.R2201Q was found in four patients 
with Dravet syndrome, but this combination was not observed in any of the control 
individuals, suggesting that the double variant is strongly associated with Dravet 
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syndrome (p = 0.0015). No statistical differences were observed for the p.K472R, 
p.E921D, p.A924G, p.E996V, p.G1108S, and p.DQER2202-2205 deletion. The silent 
mutations identified in the patients are described in Supplementary Table 2. 
A mutational analysis was conducted in the parents of the children with the SCN1A 
and CACNA1A mutations (Table 2). As far as we examined, SCN1A mutations were de 
novo in each case, whereas the CACNA1A variants were inherited from the parents. 
The p.R1126H + p.R2201Q and p.E921D + p.E996V combinations were detected in 
one parent, so both the double variants probably exist on one allele. Parents with 
CACNA1A variants suffered no neurological symptoms and had no history of 
neurological diseases, except the mother of ID #02-20 who had a history of several 
febrile seizures. 
    
Localization of the CACNA1A variants 
Variant p.G266S altered a residue within the S5-S6 pore loop of domain 1, whereas all 
other variants were located in an intracellular loop. Notably, most of the variants were 
located in the domain 2-3 loop (Fig 1B). A comparison of the amino acid sequences of 
the variants among various mammals is shown in Supplementary Fig. 1. All variants 
except p.E921D and p.A924G are conserved in mammals.  
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Genotype and Phenotype correlation 
To assess the effects of the CACNA1A variants on SCN1A mutations, phenotypic 
differences between the two groups, absence (n = 20) or presence (n = 20) of CACNA1A 
variants in the patients with SCN1A mutations were compared (Table 3). No significant 
differences were observed for the total number of seizures, or type of seizures before 
one year of age. However, the patients with both SCN1A mutations and CACNA1A 
variants showed an earlier onset of seizures and significantly more frequent prolonged 
seizures lasting for more than 10 minutes than those who had only SCN1A mutations.  
 
Biophysical properties of the novel CACNA1A variants 
Variants of CACNA1A channels were studied under identical conditions using 
heterologous expression of recombinant human Cav2.1 with the 4 and 2 accessory 
subunits in HEK 293 cells and whole-cell patch-clamp recording. We chose the novel 
variants at the conserved amino acid positions (p.G266S, p.R1126H, p.R2201Q, 
p.DQER2202-2205 deletion, and p.R1126H + p.R2201Q) for the electrophysiological 
study.  
Fig. 2A illustrates representative whole-cell currents evoked by a series of 
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depolarizing test potentials in cells expressing either WT- Cav2.1 or each of the five 
variant channels. The current-voltage relationships (Fig 2B) indicated that two of the 
five mutant channels, DQER2202-2205 deletion and the double variant R1126H + 
R2201Q had a significantly greater current density at voltages from -10 and to +10mV 
and from -10 to +60 mV than that of WT- Cav2.1. The peak current amplitudes and 
peak current densities exhibited by cells expressing DQER2202-2205 deletion or the 
R1126H + R2201Q double variant were significantly greater than those of WT- Cav2.1 
(Fig 2C). 
The voltage dependence of activation and inactivation were also examined (Fig. 3). 
Activation was significantly shifted toward more hyperpolarizing potentials in cells 
expressing the G266S, R1126H, and DQER2202-2205 deletion in comparison to 
WT-Cav2.1, whereas the other two variants activated with the same voltage dependence 
as the WT channels (Fig 3A and Table 4). Both R1126H and DQER2202-2205 deletion 
had statistically increased voltage sensitivity, as suggested by a comparison of their 
slope factors (k) with those of WT (Table 4). These findings indicate that the G266S, 
R1126H and DQER2202-2205 deletion channels will require a lower degree of 
membrane depolarization to activate, and this may contribute to neuronal 
hyperexcitability. Furthermore, activation time constants were obtained from 
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single-exponential fits of the activation phase between 0 mV and +60mV (Fig 3B). 
G266S showed a significant decrease in the time constant for activation at 20 mV in 
comparison to the WT (Fig 3C), thus suggesting that this variant may conduct a greater 
inward current during brief membrane depolarization.  
The voltage dependence of inactivation was explored by measuring the channel 
availability at +20 mV after a depolarizing 2-s pre-pulse to various test potentials. Fig 
3D and 3E illustrate the voltage dependence of inactivation and the time constants for 
inactivation at 0 mV by fitting with a two-exponential function, respectively. No 
statistically significant differences were observed between WT and the variants. 
Predicted influence of biophysical properties of these variants and novel variants on 
Cav2.1 channel activity is summarized in Table 5. 
 
Discussion 
Cav2.1 (P/Q-type) calcium channels play a role in controlling synaptic transmission 
at presynaptic nerve terminals in the mammalian central nervous system. We conducted 
a mutational analysis of all coding exons of CACNA1A in 48 patients with Dravet 
syndrome. Nine variants, including six novel variants causing amino acid changes were 
identified in 21 patients with Dravet syndrome (43.8%). Based on the incidence of 
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variants in healthy controls, the incidence of double variant p.E921D+p.E996V, 
p.A924G, and p.G1108S seemed to be common polymorphisms, whereas the p.K472R, 
p.R2201Q, and p.DQER2202-2205 deletion seemed to be relatively rare polymorphisms. 
It was noteworthy that all patients with p.R1126H also had p.R2201Q, whereas none of 
the controls had double variants (p = 0.0015). None of the parents of the patients with 
Dravet syndrome had a history of neurological disorders, except one mother with febrile 
seizures. The effect of a single CACNA1A variant alone seems to be insufficient to 
account for the neurological symptoms. 
To assess the effects of the CACNA1A variants on SCN1A mutations, we compared 
the clinical features of the patients harboring SCN1A mutations but no CACNA1A 
variants with the patients harboring SCN1A mutations and CACNA1A variants. The 
patients with SCN1A mutations and CACNA1A variants had a significantly earlier onset 
of seizures and more frequent prolonged-seizures before one year of age. This is the 
first study reporting evidence that CACNA1A variants aggravate epileptic seizures in 
Dravet syndrome patients with SCN1A mutations. 
CACNA1A mutations have been linked to familial hemiplegic migraine type 1 
(FHM1) (Ophoff et al., 1996; Ducros et al., 2001; Pietrobon, 2010), episodic ataxia type 
2 (EA2) (Ophoff et al., 1996; Guida et al., 2001), spinocerebellar ataxia type 6 
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(Zhuchenko et al., 1997; Pulst et al., 2005), and a combination of epilepsy and ataxia 
(Jouvenceau et al., 2001; Rajakulendran et al., 2010). The majority of EA2-related 
CACNA1A mutations exhibit either a complete or almost complete loss-of-function 
(Pietrobon, 2010), whereas the FHM1-related Cacna1a mutation shows a 
gain-of-function effect in synaptic transmission (van den Maagdenberg et al., 2004; 
Tottene et al., 2009; van den Maagdenberg et al., 2010).  In the present study, the 
electrophysiological properties of five novel variants were determined. Four of them 
exhibited a predicted gain-of-function, whereas R2201Q did not exhibit any significant 
difference in the parameters when compared to the WT. Interestingly, the double variant 
p.R1126H + p.R2201Q revealed a marked increase in current density, whereas that of 
the other variants were not different from the WT.  
The majority of the variants found in the patients with Dravet syndrome were 
localized in the intracellular loop of the 1 subunit. The voltage-dependent Ca2+ 
channel function can be modified by interacting with the appropriate neuronal protein, 
such as the  subunit (Pragnell et al., 1994; Walker et al., 1998), synaptic protein 
(Rettig et al., 1996; Kim and Catterall, 1997), calmodulin (Lee et al., 1999; DeMaria et 
al., 2001), and G proteins (Herlitze et al., 1996) on the intracellular loop of the 1 
subunit. These proteins regulate the biophysical properties of the Ca
2+
 channel and 
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neurotransmitter release (Catterall and Few, 2008). The double variant p.E921D + 
p.E996V was located at the synprint site, where is an interaction site between 
presynaptic proteins, including soluble N-ethylmaleimide sensitive actor attachment 
receptor (SNARE) proteins (syntaxin 1A, and synaptosome-associated protein of 25 kD 
(SNAP-25)). Syntaxin 1A and SNAP25 regulate Cav2.1 channels (Catterall and Few, 
2008), so the double variant p.E921D + p.E996V may consequently alter the interaction 
with the SNARE complex and synaptic transmission. The electrophysiological 
properties that were demonstrated in non-neuronal cells may not be equal to those in 
neuronal cells. We could not determine the precise functional interaction between 
Cav2.1 channel and Nav1.1 channel in this study. Animal models harboring double 
mutant channels will be helpful to elucidate the effects of Cav2.1 channel dysfunction 
on loss-of-function Nav1.1 channels. The genetic interactions of two different mutant 
channels, which are linked to epilepsy and neurological disease, have been investigated 
by mating mutant mice (Kearney et al., 2006; Martin et al., 2007; Glasscock et al., 
2007). Interestingly, the phenotype caused by the mutation of one channel could be 
altered by a second mutant channel, and is probably more complicated. 
In conclusion, nine variants including six novel CACNA1A variants were detected in 
21 of 48 (43.8%) patients with Dravet syndrome. As far as we examined, the variants 
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were inherited from one parent. Most of the CACNA1A variants were located in Cav2.1 
channel intracellular loops. The majority of parents with the same variant Cav2.1 
channel were asymptomatic, therefore, the effect of each variant Cav2.1 channel alone 
seem insufficient to account for the seizure phenotypes. However, the patients with 
combinations of CACNA1A variants and SCN1A mutations showed aggravated seizure 
phenotypes compared to the patients with only SCN1A mutations. The 
electrophysiological properties of novel variants of Cav2.1 channels exhibited predicted 
gain-of-function. Variants of Cav2.1 channels are potential genetic modifiers in the 
patients with Dravet syndrome. 
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Figure legends 
Figure 1: Mutations of the CACNA1A gene in patients with SMEI. (A) 
Electropherogram of CACNA1A gene DNA sequence from the patients. (B) A schematic 
diagram illustrating the transmembrane topology of the voltage-gated calcium channel 
and location of variants identified in this study. 
 
Figure 2: Comparison of Cav2.1 currents recorded in HEK293 cells expressing 
WT-CACNA1A and mutant channels. (A) Representative WT and mutant whole-cell 
Ba
2+
 currents. Whole-cell currents recorded from HEK293 cells transiently expressing 
the indicated alleles during voltage steps to various potentials between −40 to +60 mV 
with 10-mV increments from a holding potential of −100 mV. Vertical and horizontal 
scale bars represent 0.4 nA and 10 ms, respectively. (B) The current–voltage 
relationships of whole-cell Ba
2+ 
currents from transiently transfected HEK293 cells. The 
currents were elicited by test pulses to various potentials (B, inset) and normalized to 
cell capacitance (WT-CACNA1A, n=16; G266S, n=11; R1126H, n=10, R2201Q, n=8; 
Deletion2202-2205, n=8; R1126H+R2201Q, n=10). The current density of 
deletion2202-2205 and double mutation R1126H + R2201Q are significantly larger than 
WT between -10 and +10mV and -20 and +60 mV, respectively (*p<0.05). (C) 
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Distribution of the peak current amplitude (left), cell capacitance (middle), and current 
density (right) at 10 mV. *p<0.05 and **p<0.01 versus WT-CACNA1A. 
 
Figure 3: (A) Voltage dependence of activation. The voltage dependence of channel 
activation was estimated by measuring peak Ba
2+
 current during a variable test potential 
from holding potential of -100 mV. The current of each membrane potential was 
normalized to the maximum Ba
2+
 conductance. (B) Voltage dependence of activation 
time constants for WT-CACNA1A and mutants. The activation time constants were 
obtained from single-exponential fits to raw current traces at test potentials from 0 mV 
to 60 mV. (C) The activation time constants at +20 mV for WT and mutants. G266S 
showed a statistically significant decrease in activation time constant. (D) Voltage 
dependence of inactivation. The two-pulse protocol illustrated by the inset was used to 
examine the channel availability after conditioning at various potentials. The currents 
were normalized to the peak current amplitude. (WT-CACNA1A, n=10; G266S, n=10; 
R1126H, n=8, R2201Q, n=10; Deletion2202-2205, n=9; R1126H+R2201Q, n=10). (E) 
Ba
2+
 currents were evoked by 2-s test pulse. The current decay was fitted by two 
exponential functions. The mean inactivation time constants, fast (left) and slow (right), 
were plotted as a function of test potential at 0 mV. The data are expressed as the mean 
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±SEM. *p<0.05 versus WT-CACNA1A. 
Suppl. Fig. 1 legends 
Alignment of amino acid sequences in Cav2.1 calcium channel gene. The arrows 
indicate heterozygous variant sites. GenBank Accession Nos., from top to bottom, are 
NM_023035, NP_001068597, NM_001101693, NP_037050, and NP_031604. 
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Table 1 Mutational analysis of CACNA1A gene  
 
Exon 
Nucleotide 
Substitution 
Amino Acid 
Substitution 
Dravet (n=48) Control (n=188-190) 
Comments and references 
Frequency Frequency 
p 
value 
6 c.876A>G p.G266S 1/48 (2.1%) 0/188 (0%) 0.203 Novel variant 
11 c.1415A>G p.K472R 1/48 (2.1%) 1/188 (0.5%) 0.366 Novel variant 
19 c.2762A>C p.E921D 11/48 (22.9%) 49/188 (26.1)% 0.655 
Four of the 49 control individuals had homozygous variant. Previously 
reported polymorphism (dbSNP: rs16022).  
19 c.2771C>G p.A924G 1/48 (2.1%) 7/190 (3.7%) 1.0  
Novel variant. Three of the seven control individuals had homozygous 
variant. 
19 c.2987A>T p.E996V 11/48 (22.9%) 49/188 (26.1%) 0.655 
Four of the 49 control individuals had homozygous variant. Previously 
reported polymorphism (dbSNP: rs16023).   
20 c.3322G>A p.G1108S 3/48 (6.3%) 16/189 (8.5%) 0.772 
One of the 16 control individual had homozygous variant. Previously 
reported polymorphism (dbSNP: rs16027).  A small increment in current 
density (Rajakulendran et al., 2010) 
20 c.3377G>A p.R1126H 4/48 (8.3%) 1/188 (0.5%) 0.0066 Novel variant.  All individual with minor variant were heterozygous.  
47 c.6602G>A p.R2201Q 4/48 (8.3%) 4/189 (2.1%) 0.055 Novel variant.  All individual with minor variant were heterozygous.  
47 c.6605-6616del p.DQER2202-2205del 1/48 (2.1%) 3/190 (1.6%) 1.0  Novel variant 
Frequency of combined variants 
Dravet  Control  
Comments and references 
Frequency Frequency 
p 
value 
19 
c.2762A>C 
+c.2987A>T 
E921D+E996V 11/48 (22.9%) 49/188 (26.1%) 0.2 
Previously reported polymorphism.  A reduction of current density and 
depolarizing shift in activation (Rajakulendran et al., 2010) 
20+47 
c.3377G>A  
+c.6602G>A 
R1126H      
+R2201Q 
4/48 (8.3%) 0/188 (0%) 0.0015 
Both variants were likely to be located on the same allele in all of the four 
patients.   All individual with minor variant were heterozygous.  
 
Table 1
Table 2: Inheritance of CACNA1A variants and SCN1A mutations  
     
Patients 
CACNA1A gene SCN1A gene 
Variants 
Inheritance 
Mutations 
Inheritance 
Father Mother De novo? 
03-8 p.G266S       p.G266S - p.G177R ¶ Yes 
05-46 p.K472R       NA NA p.W738fsX746 ¶ NA 
01-55 p.A924G       - p.A924G p.V1390M * Yes 
04-12 p.E921D  p.E996V      NA NA p.V212A ¶ NA 
02-23 p.E921D  p.E996V      p.E921D + p.E996V - p.R377L ¶ Yes 
01-28 p.E921D  p.E996V      NA NA Deletion of exon 10 ¶ NA 
01-19 p.E921D  p.E996V      - p.E921D + p.E996V p.P707fsX714 * Yes 
01-29 p.E921D  p.E996V      p.E921D + p.E996V - p.R865X * Yes 
01-49 p.E921D  p.E996V      NA NA p.F902C * NA 
01-7 p.E921D  p.E996V      p.E921D + p.E996V p.E921D + p.E996V p.T1082fsX1086 * Yes 
02-27 p.E921D  p.E996V      NA NA p.Q1277X ¶ NA 
01-4 p.E921D  p.E996V      p.E921D + p.E996V - p.Q1450R * Yes 
02-20 p.E921D  p.E996V      NA p.E921D + p.E996V p.A1685D ¶ NA 
02-2 p.E921D  p.E996V  p.R1126H  p.R2201Q  NA p.R1126H + p.R2201Q p.T1909I * NA 
06-12 p.R1126H  p.R2201Q      - p.R1126H + p.R2201Q p.G163E ¶ Yes 
01-16 p.R1126H  p.R2201Q      p.R1126H + p.R2201Q - p.R501fsX543 * Yes 
02-24 p.R1126H  p.R2201Q      - p.R1126H + p.R2201Q p.S1574X * Yes 
05-06 p.DQER2202-2205del       NA - negative   NA 
01-22 p.G1108S       - p.G1108S p.R712X * Yes 
01-35 p.G1108S       NA p.G1108S p.R1648C * NA 
21 p.G1108S       NA NA negative   NA 
NA; Agreement of the mutational analysis was not available, -; the same mutations were not detected. Sequences of each sample were compared with the GenBank data 
base (accession numbers: NM_023035 and AB093548). *, ¶These mutations were previously reported in our paper, BBRC (2002)* and Epilpesia (2008)¶ 
 
Table 2
Table 3: Genotype-phenotype correlation before one year of age 
Genotype N 
SCN1A mutations  Seizure 
onset    
mean±SEM  
(months) 
Total no. of 
seizures    
mean±SEM 
Total no. of 
prolonged 
(>10min)  
seizures       
mean±SEM 
Type of Seizures 
missense   
N (%) 
Truncation
, deletion       
N (%) 
GTC (%) CPS (%) 
Hemi- 
convulsion 
(%) 
Myoclonic 
seizure (%) 
SCN1A mutations +                          
No CACNA1A variants 
20 9 (45%) 11 (55%) 5.6±0.3 10.2±1.2 2.5±0.4 95 45 50 15 
SCN1A mutations +            
CACNA1A variants 
20 10 (50%) 10 (50%) 4.6±0.4* 11.3±1.4 4.7±0.7* 95 30 80 10 
GTC: generalized tonic-clonc seizure,  CPS: complex partial seizure *p<0.05 versus the patients with SCN1A mutations + no CACNA1A variants 
 
 
Table 3
Table 4. Biophysical parameters for activation and inactivation 
          Activation   Inactivation 
  V1/2 (mV) k (mV) n   V1/2 (mV) k (mV) n 
WT-CACNA1A 6.3±1.3 4.3±0.2 16 
 
-16.9±1.5 -4.5±0.6 10 
G266S 1.0±1.2** 4.3±0.4 11 
 
-13.8±1.6 -5.5±0.3 10 
R1126H 0.4±1.6** 3.3±0.3* 10 
 
-18.9±0.6 -6.1±0.7 8 
R2201Q 6.4±1.5 4.1±0.2 8 
 
-13.4±1.7 -5.7±0.4 10 
Deletion2202-2205 1.3±1.4* 3.4±0.2* 8 
 
-13.3±1.2 -4.7±0.6 9 
R1126H+R2201Q 2.6±1.1 3.5±0.2 10   -15.2±0.9 -5.4±0.1 10 
V1/2, half-maximal voltage activation and inactivation; k, slope factor. Statistical coparison between  WT-CACNA1A and 
mutant channels was performed by Student's t test (*P<0.05 and **P<0.01 versus WT-CACNA1A). 
 
Table 4
Table 5.    Predicted influence of biophysical properties on Cav2.1 channels activity 
  CACNA1A 
Biophysical property G266S R1126H R2201Q Del 2202-2205 
R1126H+  
R2201Q 
Peak current density - - - ↑ ↑ 
Activation V1/2 ↑ ↑ - ↑ - 
Activation slop factor - ↑ - ↑ - 
Inactivation V1/2 - - - - - 
Inactivation slope factor - - - - - 
↑, predicted gain of channel activity, ↓, predicted loss of channel activity, -, no predicted change in channel 
activity. 
 
Table 5
Supplementary table 1: SCN1A mutations in patients with Dravet syndrome 
  
SCN1A mutations 
Family history 
Nucleotide Substitution Amino Acid Substitution 
06-12 c.488G>A p.G163E ¶ Maternal aunt:FS 
03-8 c.529G>A p.G177R ¶ negative 
04-12 c.635T>C p.V212A ¶ negative 
02-23 c.1130G>T p.R377L ¶ negative 
01-40 c.1502deletionG p.R501fsX543 * Paternal aunt:Ep 
01-16 c.1641insA p.K547fsX570 * negative 
05-18 c.1702C>T p.R568X * negative 
01-56 c.1820deletionC p.S607fsX622 * negative 
01-19 c.2120deletionC p.P707fsX714 * negative 
01-22 c.2134C>T p.R712X * Father:FS 
05-46 c.2213deletionG  p.W738fsX746 ¶ negative 
03-22 c.2362G>A p.E788K ¶ negative 
01-29 c.2593C>T p.R865X * Brother:FS 
01-49 c.2705T>G p.F902C * Brothers:FS, Maternal grandfather:convulsion 
02-3 c.2791C>T p.R931C * negative 
01-37 c.2791C>T p.R931C * negative 
05-52 c.2970G>T p.L990F ¶ Father&paternal uncle: FS, Maternal uncle:FS 
01-46 c.3006deletionC p.A1002fsX1009 * Paternal uncle:FS 
01-1 c.3079A>T p.K1027X * Paternal aunt:FS 
22 
c.3170-31833del 
(AGAAAGACAGTTGT) ins 
(TCATTCTGTATG) 
p.K1057fsX1073 Novel negative 
01-7 c.3245deletionC p.T1082fsX1086 * Maternal cousin:convulsion  
01-25 c.3794T>C p.L1265P * negative 
02-9 c.3812G>A p.W1271X * Maternal cousin:FS 
02-27 c.3829C>T p.Q1277X ¶ Sister:convulsion 
02-6 c.3867-3869deletionCTT p.1289delF * Father, sister:FS 
01-55 c.4168G>A p.V1390M * negative 
03-66 IVS21-2A>G 
Intron 21 splicing 
error 
¶ Maternal cousin:FS, Paternal cousin:FS 
02-10 
c.4286-4290del(CCACA) 
ins(ATGTCC) 
p.A1429fsX1443 * Maternal uncle:Ep 
01-60 c.4300T>C p.W1434R * negative 
01-4 c.4349A>G p.Q1450R * negative 
05-11 c.4615A>C p.T1539P ¶ negative 
04-09 c.4721C>G p.S1574X ¶ Mother's cousin: Ep 
02-24 c.4721C>G p.S1574X * negative 
01-35 c.4942C>T p.R1648C * negative 
Suppl. Table 1
01-52 c.5020G>C p.G1674R * negative 
06-14 c.4985C>T p.A1662V Novel negative 
02-20 c.5054C>A p.A1685D ¶ Mother:FS 
02-14 
c.5640-5645 del(AGAGAT) 
ins(CTAGAGTA) 
p.G1880fsX1881 * negative 
02-2 c.5726C>T p.T1909I * negative 
01-28   
Deletion of exon 
10 
¶ Father, Paternal grandfather:FS 
02-16   negative   negative 
01-32   negative   Brother:FS 
01-43   negative   Mother:Ep 
02-15   negative   Brother:SMEI, Paternal grandfather:Ep 
03-46   negative   Maternal grandfather:Ep 
05-07   negative   negative 
05-06   negative   Mother, sister, maternal uncle: FS 
21   negative   negative 
     FS; Febrile seizure, Ep; Epilepsy, NE; not examined 
Sequences of each sample were compared with the GenBank data base (accession number: AB093548) 
*, ¶These mutations were previously reported in our paper, BBRC (2002)* and Epilpesia (2008)¶ 
 
Supplementary table 2: Silent mutations in coding regions of the CACNA1A gene 
Exon amino acid Allele Frequency SNP reference 
6 p.292E 
GAA/GAA GAA/GAG GAG/GAG 
rs16006 
40 7 1 
8 p.394E 
GAA/GAA GAA/GAG GAG/GAG 
rs2248069 
22 21 5 
12 p.524I 
ATT/ATT ATT/ATA   
rs16010 
47 1 0 
16 p.697T 
ACG/ACG ACG/ACA ACA/ACA 
rs16016 
21 25 2 
19 p.1019R 
AGG/AGG AGG/AGA AGA/AGA 
rs16025 
37 11 0 
23 p.1287F 
TTT/TTT TTT/TTC TTC/TTC 
rs16030 
40 8 0 
27 p.1454T 
ACC/ACC ACC/ACT ACT/ACT 
- 
47 1 0 
28 p.1468S 
TCG/TCG TCG/TCA TCA/TCA 
- 
47 1 0 
39 p.1884V 
GTC/GTC GTC/GTT GTT/GTT 
rs17846921 
46 2 0 
47 p.2219H 
CAT/CAT CAT/CAC CAC/CAC 
rs16051 
2 17 29 
       
Suppl. Table 2
